BRPI0923422A2 - promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor " - Google Patents

promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "

Info

Publication number
BRPI0923422A2
BRPI0923422A2 BRPI0923422A BRPI0923422A BRPI0923422A2 BR PI0923422 A2 BRPI0923422 A2 BR PI0923422A2 BR PI0923422 A BRPI0923422 A BR PI0923422A BR PI0923422 A BRPI0923422 A BR PI0923422A BR PI0923422 A2 BRPI0923422 A2 BR PI0923422A2
Authority
BR
Brazil
Prior art keywords
infections
graft
versus
maintains
prophylactic agent
Prior art date
Application number
BRPI0923422A
Other languages
English (en)
Inventor
Matsushima Kouji
Shono Yusuke
Ueha Satoshi
Original Assignee
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo filed Critical Univ Tokyo
Publication of BRPI0923422A2 publication Critical patent/BRPI0923422A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0923422A 2008-12-12 2009-11-04 promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor " BRPI0923422A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008316828 2008-12-12
PCT/JP2009/068805 WO2010067671A1 (ja) 2008-12-12 2009-11-04 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤

Publications (1)

Publication Number Publication Date
BRPI0923422A2 true BRPI0923422A2 (pt) 2016-06-21

Family

ID=42242663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923422A BRPI0923422A2 (pt) 2008-12-12 2009-11-04 promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "

Country Status (5)

Country Link
US (1) US9156912B2 (pt)
JP (1) JP5688734B2 (pt)
CN (1) CN102271711B (pt)
BR (1) BRPI0923422A2 (pt)
WO (1) WO2010067671A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471543A1 (en) * 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
AU2013226944B2 (en) * 2012-02-29 2017-03-23 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
ES2862950T3 (es) * 2012-12-18 2021-10-08 Univ Rockefeller Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH
EP3132802B1 (en) * 2014-02-21 2020-06-17 IDAC Theranostics, Inc. Therapeutic agent for solid cancer
JP6715491B2 (ja) * 2014-06-11 2020-07-01 Ｉｄａｃセラノスティクス株式会社 免疫チェックポイント制御剤の副作用低減方法
JP7305539B2 (ja) * 2016-11-02 2023-07-10 ウニベルシテート バーゼル 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体
EP3585404A4 (en) * 2017-02-23 2021-04-14 City of Hope METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD)
EP4039259B1 (en) 2017-03-15 2024-01-24 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
CN115887493A (zh) * 2022-07-04 2023-04-04 北京大学人民医院 Nk细胞的应用、nk细胞回输制剂以及组合制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653684B2 (ja) 1987-12-02 1994-07-20 ベクトン・ディッキンソン・アンド・カンパニー 移植片対宿主病を防ぐための薬剤キット
US5178858A (en) 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
CA2386192A1 (en) * 1999-10-07 2001-04-12 Avi Biopharma, Inc. C-myc antisense-treated hematopoietic stem cell composition and method
JP2003246751A (ja) * 2002-02-22 2003-09-02 Sumitomo Pharmaceut Co Ltd 骨髄移植後合併症治療剤
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells

Also Published As

Publication number Publication date
WO2010067671A1 (ja) 2010-06-17
US9156912B2 (en) 2015-10-13
US20120027748A1 (en) 2012-02-02
CN102271711B (zh) 2014-06-18
CN102271711A (zh) 2011-12-07
JP5688734B2 (ja) 2015-03-25
JPWO2010067671A1 (ja) 2012-05-17

Similar Documents

Publication Publication Date Title
BRPI0923422A2 (pt) promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "
HK1225961A1 (zh) 治療或預防金黃色葡萄球菌感染以及根除或減少表面上金黃色葡萄球菌的組合物和方法
GB2467685B (en) Risk scoring system for the prevention of malware
IL236054B (en) Compositions and methods for treating Crohn's disease and related conditions and infections
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
EP2001516A4 (en) VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
IL213489A0 (en) Compositions and methods for the treatment of the prevention of e. coli infections and for the eradication or reduction of e. coli surfaces
NO20091183L (no) Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
FR23C1002I1 (fr) 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
IT1398451B1 (it) Sistema e metodo per la localizzazione di persone e/o oggetti all'interno di edifici.
BRPI1016257A2 (pt) composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais
SMT201600190B (it) Uso di streptococcus salivarius nel trattamento di infezioni croniche dell'apparato respiratorio
HK1151304A1 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
IL197783A0 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
ITMI20080195A1 (it) Procedimento per la preparazione di solifenacin
EP2249843A4 (en) USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGENIC INFECTIONS
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
FI20065456A0 (fi) Maitotuotteiden rakenteen parantaminen
FR2941864B1 (fr) Substance active pour la protection de fgf-2
ITRM20060027A1 (it) Apparecchiatura per l asciugatura di prodotti fogliacei

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2385 DE 20/09/2016.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 9A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28/08/2018.